(Q42272174)

English

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

scientific article published on 28 February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

Giuseppe Remuzzi

13

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

object named as

John J McMurray

10

0 references

18

object named as

Janet Wittes

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

David G Warnock

17

object named as

David G Warnock

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Hans-Henrik Parving

11

object named as

Hans-Henrik Parving

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

14

object named as

Robert D Toto

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

2

object named as

Tadao Akizawa

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

4

object named as

Paul Audhya

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

5

object named as

George L Bakris

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

6

object named as

Melanie Chin

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

7

object named as

Melissa Krauth

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Hiddo J L Heerspink

8

object named as

Hiddo J Lambers Heerspink

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

9

object named as

Colin J Meyer

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Nosratola D Vaziri

15

object named as

Nosratola D Vaziri

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

19

object named as

Glenn M Chertow

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

author name string

Dick de Zeeuw

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Rajiv Agarwal

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Pablo E Pergola

12

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Christoph Wanner

16

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

publication date

28 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

American Journal of Nephrology

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

212-222

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

The kidney in type 2 diabetes therapy

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Effect of a multifactorial intervention on mortality in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Pyridorin in type 2 diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Avosentan for overt diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Rapid progression of diabetic nephropathy is linked to inflammation and episodes of acute renal failure

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Inflammation as a risk factor and target for therapy in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis.

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Evaluation of the modification of diet in renal disease study equation in a large diverse population.

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Preparing renal replacement therapy in stage 4 CKD patients referred to nephrologists: a difficult balance between futility and insufficiency. A cohort study of 386 patients followed in Brussels

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Serum phosphate and mortality in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Monitoring kidney function and albuminuria in patients with diabetes

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

How does proteinuria cause progressive renal damage?

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Bardoxolone methyl decreases megalin and activates nrf2 in the kidney

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Sulodexide for Kidney Protection in Type 2 Diabetes Patients With Microalbuminuria: A Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1159%2F000346948

21 January 2018

Identifiers

10.1159/000346948

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42272174&oldid=2039582668"